Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Pedestrian Footbridges on Economic, Health and Educational Outcomes in Rural Communities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03955562
Recruitment Status : Unknown
Verified May 2019 by Evan Thomas, University of Colorado, Boulder.
Recruitment status was:  Recruiting
First Posted : May 20, 2019
Last Update Posted : May 20, 2019
Sponsor:
Collaborators:
Yale University
University of Notre Dame
University of Colorado, Denver
Information provided by (Responsible Party):
Evan Thomas, University of Colorado, Boulder

Brief Summary:

Isolation caused by lack of transportation infrastructure affects almost every facet of life for the rural poor. Without adequate transportation access, families cannot access schools, health care, employment, or local markets to sell and buy goods. The World Bank estimates that nearly a billion people worldwide lack access to an all-season road within two kilometers, illustrating the scope of the problem, and the challenge of addressing it at scale.

Bridges to Prosperity (B2P) is a non-profit organization that builds footbridges to connect rural communities facing isolation to road networks and critical destinations and services. B2P has constructed more than 280 footbridges in 20 countries, an infrastructure intervention that is cost-effective, durable, and relatively simple to scale. B2P's field program in Rwanda started in 2012 and has led to the completion of 37 footbridges that have created new safe access for an estimated 225,000 people. Over the next five years, B2P plans to construct approximately 350 footbridges in Rwanda. This rapid program growth presents an unprecedented opportunity for rigorous investigation of the effects of new footbridges on a number of key economic, health, agricultural and education outcomes for rural communities.

As such, the research team has been brought on to carry out an impact evaluation of B2P-constructed footbridges in rural Rwanda. This protocol is for the first phase of the study and will focus on 12 footbridge sites and 12 comparison sites over the course of one year, while the larger study will encompass approximately 350 sites over the planned five-year construction period. The results of this first phase will inform the design of the larger study.


Condition or disease Intervention/treatment Phase
Head of Household Other: Footbridge Other: Comparison villages Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2400 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study will be a matched-cohort study, in which twelve bridge sites will be matched to twelve comparison sites. The bridge sites have been defined and identified by B2P staff in conjunction with government officials through a systematic needs assessment carried out in 2014. Of the twelve bridge sites that have been confirmed for the study, seven are located in the Southern Province, and five are located in the Western Province. Comparison sites were identified from a 2018 needs assessment carried out by B2P. As with the bridge sites, seven of the comparison sites are in the Southern Province and five are in the Western Province. The table of bridge and control sites with their respective districts and provinces can be found in Appendix A.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Impact of Pedestrian Footbridges on Economic, Health and Educational Outcomes in Rural Communities
Actual Study Start Date : February 15, 2019
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : March 1, 2020

Arm Intervention/treatment
Experimental: Intervention
Communities that receive a pedestrian footbridge.
Other: Footbridge
Access to a pedestrian footbridge.

Experimental: Comparison
Communities that do not receive a pedestrian footbridge.
Other: Comparison villages
Villages that do not receive a footbridge.




Primary Outcome Measures :
  1. Household food expenditure [ Time Frame: 18 months ]
    Rwandan francs - percentage change from baseline Household representatives will be asked survey questions regarding the prices and quantities of consumption of food items to determine total household expenditure on food, including distinction between own-produced food and market purchases.

  2. Household income [ Time Frame: 18 months ]
    Rwandan francs - percentage change from baseline Household representatives will be asked survey questions regarding the income generating activities of adults in the household and the amount of income from each activity to determine total household income.

  3. Household use of fertilizer [ Time Frame: 18 months ]
    Yes/no - change in percentage Household representatives will be asked whether or not their household uses fertilizer when growing crops.

  4. Monetary value of livestock [ Time Frame: 18 months ]
    Rwandan francs - percentage change from baseline Household representatives will be asked survey questions regarding the types, quantities, and value of livestock their household owns.

  5. Work outside of community [ Time Frame: 18 months ]
    Yes/no - change in percentage yes/no) - change in percentage Household representatives will be asked survey questions regarding the location of work for adults in the household, and specifically whether individuals leave the community to work daily, seasonally or for longer periods of time.

  6. Access to health care [ Time Frame: 18 months ]
    Yes/no - change in percentage Household representatives will be asked whether or not household members have visited a health clinic in the last month.

  7. Mid-upper arm circumference (MUAC) [ Time Frame: 18 months ]
    Centimeters - percentage change from baseline With household representative's permission, the MUAC of children in the household between 6 months and 5 years will be measured using an MUAC tape.


Secondary Outcome Measures :
  1. Child enrollment in school [ Time Frame: 18 months ]
    Household representatives will be asked whether the children in the household are enrolled in school

  2. Days of school missed [ Time Frame: 18 months ]
    Household representatives will be asked how many days of school each child attending school missed in the past month

  3. Access to prenatal care [ Time Frame: 18 months ]
    If the household representative is pregnant or a household member under 18 is pregnant, the household representative will be asked if the pregnant woman or girl has visited a clinic for prenatal care during the current pregnancy.

  4. Type of prenatal services received [ Time Frame: 18 months ]
    If prenatal services have been received by a household member during a current pregnancy, the household representative will be asked what type of services were received.

  5. Prenatal tetanus vaccination [ Time Frame: 18 months ]
    If the household representative is pregnant or a household member under 18 is pregnant, the enumerator will request to see their vaccination card and document whether they have received their tetanus vaccine. If the card is not available or the respondent does not want to show the card, the enumerator will ask if the pregnant person has received their tetanus vaccine.

  6. Child vaccination [ Time Frame: 18 months ]
    For children under 5 years of age, the enumerator will ask to see their vaccination cards and, if available, document what vaccines the child has received. If not available or not made available, the enumerator will ask the household representative which vaccines the child has received.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Random selection of first 100 households in a village from administrative data
  • Head of household in intervention and comparison villages

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03955562


Contacts
Layout table for location contacts
Contact: Evan Thomas, PhD 3035504671 ethomas@colorado.edu
Contact: Laura MacDonald, PhD 7206212501 laura.a.macdonald@colorado.edu

Locations
Layout table for location information
Rwanda
Communities in Rwanda Recruiting
Kigali, Rwanda
Contact: Laura A MacDonald, PhD    7206212501    laura.a.macdonald@colorado.edu   
Sponsors and Collaborators
University of Colorado, Boulder
Yale University
University of Notre Dame
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Evan Thomas, PhD University of Colorado, Boulder
Layout table for additonal information
Responsible Party: Evan Thomas, Associate Professor & Mortenson Endowed Chair in Global Engineering, and Director, Mortenson Center, University of Colorado, Boulder
ClinicalTrials.gov Identifier: NCT03955562    
Other Study ID Numbers: 18-0739
First Posted: May 20, 2019    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No